Category: C.R. Bard
Some 650 lawsuits filed in an Oklahoma court over its pelvic mesh products ought to be treated as a mass action in federal court, Johnson & Johnson subsidiary Ethicon argued this week.
The plaintiffs in some 650 product liability lawsuits filed in an Oklahoma court over Ethicon's pelvic mesh products are improperly looking to exclude them from mass action status, the Johnson & Johnson (NYSE:JNJ) subsidiary argued this week in a federal appeals court.
The Philadelphia Court of Common Pleas establishes a mass tort for all pelvic mesh lawsuits filed in its jurisdiction.
A Pennsylvania state judge ordered the creation of a mass tort this week to collect product liability lawsuits filed over pelvic mesh products against some of the largest names in medical devices.
Judge Arnold New, director of the Complex Litigation Center at the Philadelphia Court of Common Pleas, ordered Feb. 11 that "all currently filed pelvic mesh matters shall be transferred to the Complex Litigation Center Pelvic Mesh Mass Tort Program" for coordination, according to court documents.
C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.
A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.
A federal judge orders the selection of 200 lawsuits for discovery proceedings in the multi-district litigation over C.R. Bard's Avaulta pelvic mesh products.
The mass tort against C.R. Bard (NYSE:BCR) is about to generate an avalanche of paper after a federal judge ordered the plaintiffs and Bard to choose some 200 lawsuits for discovery.
A bellwether trial in the multi-district litigation against C.R. Bard over its recalled Avaulta pelvic mesh is delayed after the wife of a key witness is hospitalized.
The urgent hospitalization of the wife of a key witness prompted a federal judge to indefinitely postpone a bellwether trial in the multi-district litigation over C.R. Bard's (NYSE:BCR) recalled Avaulta pelvic mesh.
C.R. Bard won't be allowed to exclude internal memos about its recalled Avaulta pelvic mesh from a bellwether product liability trial, a federal judge ruled last week.
C.R. Bard (NYSE:BCR) won't be able to keep internal memos out of an upcoming bellwether trial over its recalled Avaulta pelvic mesh, a federal judge ruled last week.
MassDevice.com looks into the tea leaves to peek at medtech's near future with our 3 predictions for the new year.
As we put a ribbon on 2013, another tumultuous year for the medical device industry, it's time to check the tea leaves for what medtech might expect in 2014.
These predictions are based on the 2,500 or so stories we've written this year about the medical device space, as well as conversations we've had with hundreds of industry leaders about their thoughts, concerns, annoyances and triumphs.
Prediction #1: The medical device tax will not survive 2014